

Form PTO-1449 (Modified) FEB 19 2003 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION	U.S. Department of Commerce Patent and Trademark Office	Serial No. 10/045,884	Group Art Unit 1617	Filing Date 01/09/02	Atty. Docket No. Le A 34 992
	Applicant(s) Fahrig, et al.				

U.S. PATENT DOCUMENTS													
*	DOCUMENT NO.								DATE MM/DD/YY	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS														
		DOCUMENT NO.							DATE DD/MM/YY	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION	
		YES	NO											
SW	F4	9	9	2	9	3	4	6	17/06/99	WO	A61K	45/06		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)		
SW	R4	Abstract XP-002221547, various, Merck Manual, pgs. 1466-1467 (1999)
SW	R5	Kukley, M., Schaper, C., Becker, A., Rose, K., Krieglstein, J., "Effect of 5-Hydroxytryptamine 1A Receptor Agonist Bay X 3702 on BCL-2 and Bax Proteins Level in the Ipsilateral Cerebral Cortex of Rats After Transient Focal Ischaemia", Neuroscience, <u>107</u> : 405-413 (2001)
SW	R6	Semkova, I., Wolz, P., Krieglstein, J., "Neuroprotective Effect of 5-HT _{1A} Receptor Agonist, Bay X 3702, Demonstrated in Vitro and in Vivo", Eu. J. of Pharmacology, <u>359</u> : 251-260 (1998)
SW	R7	Kline, A., Yu, J., Horvath, E., Marion, D., Dixon, C., "The Selective 5-HT _{1A} Receptor Agonist Repinotan HCL Attenuates Histopathology and Spatial Learning Deficits Following Traumatic Brain Injury in Rats", Neuroscience, <u>106</u> : 547-555 (2001)

EXAMINER G. L. V.	DATE CONSIDERED 5/30/03
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	